H. Kantarjian, S. O'brien, Xuelin Huang
Mar 15, 2007
Citations
3
Influential Citations
134
Citations
Quality indicators
Journal
Cancer
Abstract
Decitabine, a hypomethylating agent, is active and has been approved for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia. Intensive chemotherapy is an accepted form of therapy for patients with higher risk MDS. The comparative efficacy of these 2 forms of treatment in MDS is unknown. The objective of the current study was to compare the efficacy and toxicity profiles of decitabine and intensive chemotherapy in MDS.